Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis

References

• Ahmad, N., S. D. Ahuja, O. W. Akkerman, J.-W. C. Alffenaar, L. F. Anderson, P. Baghaei, D. Bang, et al. 2018. “Treatment Correlates of Successful Outcomes in Pulmonary Multidrug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.” The Lancet 392 (10150): 821–834. doi:10.1016/S0140-6736(18)31644-1.
   PubMed Web of Science ®Google Scholar
• American Speech-Language-Hearing Association. 1994. “Audiologic management of individuals receiving cochleotoxic drug therapy.” [Internet]. Accessed 12 July 2018. http://www.asha.org/policy/GL1994-00003/.
   Google Scholar
• Brits, J., S. Strauss, Z. Eloff, P. J. Becker, and D. W. Swanepoel. 2012. “Hearing Profile of Gold Miners with and without Tuberculosis.” Occupational and Environmental Medicine 69 (4): 243–249. doi:10.1136/oemed-2011-100106.
   PubMed Web of Science ®Google Scholar
• Caminero, J. A., G. Sotgiu, A. Zumla, and G. B. Migliori. 2010. “Best Drug Treatment for Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.” The Lancet Infectious Diseases 10 (9): 621–629. doi:10.1016/S1473-3099(10)70139-0.
   PubMed Web of Science ®Google Scholar
• Crundwell, G., P. Gomersall, and D. M. Baguley. 2016. “Ototoxicity (Cochleotoxicity) Classifications: A Review.” International Journal of Audiology 55 (2): 65–74. doi:10.3109/14992027.2015.1094188.
   PubMed Web of Science ®Google Scholar
• de Jager, P., and R. van Altena. 2002. “Hearing Loss and Nephrotoxicity in Long-Term Aminoglycoside Treatment in Patients with Tuberculosis.” The International Journal of Tuberculosis and Lung Disease 6 (7): 622–627.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. 2011. “Guideline on Bioanalytical Method Validation.” [Internet]. Accessed 13 July 2018. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.
   Google Scholar
• Ghafari, N., C. Rogers, L. Petersen, and S. A. Singh. 2015. “The Occurrence of Auditory Dysfunction in Children with TB Receiving Ototoxic Medication at a TB Hospital in South Africa.” International Journal of Pediatric Otorhinolaryngology 79 (7): 1101–1105. doi:10.1016/j.ijporl.2015.04.040.
   PubMed Web of Science ®Google Scholar
• Harris, A., S. Bardien, H. S. Schaaf, L. Petersen, G. de Jong, and J. F. Johannes. 2012. “Aminoglycoside-Induced Hearing Loss in HIV-Positive and HIV-Negative Multidrug-Resistant Tuberculosis Patients.” South African Medical Journal 102 (6): 363–366. doi:10.7196/samj.4964.
   PubMed Web of Science ®Google Scholar
• Heysell, S. K., S. Ahmed, M. T. Rahman, M. W. Akhanda, A. T. Gleason, A. Ebers, E. R. Houpt, and S. Banu. 2018. “Hearing Loss with Kanamycin Treatment for Multidrug-Resistant Tuberculosis in Bangladesh.” European Respiratory Journal 51 (3): pii: 1701778. doi:10.1183/13993003.01778-2017.
   Web of Science ®Google Scholar
• Human, H., C. M. Hagen, G. de Jong, T. Harris, D. Lombard, M. Christiansen, S. Bardien, et al. 2010. “Investigation of Mitochondrial Sequence Variants Associated with Aminoglycoside-Induced Ototoxicity in South African TB Patients on Aminoglycosides.” Biochemical and Biophysical Research Communications 393 (4): 751–756. doi:10.1016/j.bbrc.2010.02.075.
   PubMed Web of Science ®Google Scholar
• King, K. A., and C. C. Brewer. 2018. “Clinical Trials, Ototoxicity Grading Scales and the Audiologist’s Role in Therapeutic Decision Making.” International Journal of Audiology 57 (sup. 4): S89–S98. doi:10.1080/14992027.2017.1417644.
   PubMedGoogle Scholar
• Kokotas, H., M. Petersen, and P. Willems. 2007. “Mitochondrial Deafness.” Clinical Genetics 71 (5): 379–391. doi:10.1111/j.1399-0004.2007.00800.x.
   PubMed Web of Science ®Google Scholar
• Modongo, C., J. G. Pasipanodya, N. M. Zetola, S. M. Williams, G. Sirugo, and T. Gumbo. 2015. “Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients.” Antimicrobial Agents and Chemotherapy 59 (10): 6337–6343. doi:10.1128/AAC.01050-15.
   PubMed Web of Science ®Google Scholar
• Momin, M. A. M., S. Sinha, I. G. Tucker, C. Doyle, and S. C. Das. 2017. “Dry Powder Formulation of Kanamycin with Enhanced Aerosolization Efficiency for Drug-Resistant Tuberculosis.” International Journal of Pharmaceutics 528 (1–2): 107–117. doi:10.1016/j.ijpharm.2017.06.004.
   PubMed Web of Science ®Google Scholar
• Ramma, L. 2016. “An Alternative Grading System for Ototoxicity in Adults: Towards a Uniform International Standard for Grading Ototoxicity.” Paper presented at the 3rd International Conference and Exhibition on Rhinology & Otology, Dubai, UAE.
   Google Scholar
• Ramma, L., and T. S. Ibekwe. 2012. “Cochleo-Vestibular Clinical Findings among Drug Resistant Tuberculosis Patients on Therapy – A Pilot Study.” International Archives of Medicine 5 (1): 3. doi:10.1186/1755-7682-5-3.
   PubMedGoogle Scholar
• South African Department of Health. 2013. “Management of Drug-Resistant Tuberculosis.” https://www.health-e.org.za/wp-content/uploads/2014/06/MDR-TB-Clinical-Guidelines-Updated-Jan-2013.pdf.
   Google Scholar
• Sturdy, A., A. Goodman, R. J. Jose, A. Loyse, M. O’Donoghue, O. M. Kon, M. J. Dedicoat, et al. 2011. “Multidrug-Resistant Tuberculosis (MDR-TB) Treatment in the UK: A Study of Injectable Use and Toxicity in Practice.” Journal of Antimicrobial Chemotherapy 66 (8): 1815–1820. doi:10.1093/jac/dkr221.
   PubMed Web of Science ®Google Scholar
• Theunissen, E. A. R., W. A. Dreschler, M. N. Latenstein, C. R. N. Rasch, S. van der Baan, J. P. de Boer, A. J. M. Balm, and C. L. Zuur. 2014. “A New Grading System for Ototoxicity in Adults.” Annals of Otology, Rhinology & Laryngology 123 (10): 711–718. doi:10.1177/0003489414534010.
   PubMed Web of Science ®Google Scholar
• US Foods & Drug Administration Center for Drug Evaluation and Research. 2018. Bioanalytical method validation: guidance for industry. Washington DC, USA: FDA. https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Accessed November 2019.
   Google Scholar
• van Altena, R., J. A. Dijkstra, M. E. van der Meer, J. F. Borjas Howard, J. G. W. Kosterink, D. van Soolingen, T. S. van der Werf, and J. W. Alffenaar. 2017. “Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis.” Antimicrobial Agents and Chemotherapy 61 (3): pii: e01400-16. doi:10.1128/AAC.01400-16.
   Web of Science ®Google Scholar
• WHO. 2018. “Rapid Communication: Key Changes to Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis (MDR/RR-TB).” [Internet]. Accessed 6 December 2018. https://www.who.int/tb/publications/2018/WHO_RapidCommunicationMDRTB.pdf?ua=1.
   Google Scholar